• Users Online: 252
  • Print this page
  • Email this page
CASE REPORT
Year : 2020  |  Volume : 20  |  Issue : 2  |  Page : 90-92

Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window


Department of Neurology, University Hospital Dubrava, Zagreb, Croatia

Correspondence Address:
Dr. Sabina Deveđija*
Department of Neurology, University Hospital Dubrava, Zagreb 10000
Croatia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2452-2473.285015

Rights and Permissions

Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80-year-old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 8. Dabigatran was reversed with idarucizumab, and intravenous tissue-type plasminogen activator (IV-tPA) was administrated beginning 4 h and 28 min after the symptom onset. The patient was discharged with an NIHSS of 1. Our case is an additional proof of safety and efficiency of idarucizumab in the clinical setting of ischemic stroke before the administration of IV-tPA.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed263    
    Printed2    
    Emailed0    
    PDF Downloaded35    
    Comments [Add]    

Recommend this journal